SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Recruiting · NCT07131319 · Interventional (participants receive a specific treatment) · Lead sponsor: Second Affiliated Hospital of Nanchang University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are: Will spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection rate of patients with initially unresectable stage Ⅲ non-small cell lung cancer? What adverse reactions will patients experience when receiving spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment?
Who can take part
Inclusion criteria
- The patient has histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) that is deemed unresectable after discussion in the multidisciplinary team (MDT), which is classified as T3-4N1-2M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC).
Exclusion criteria
- Has participated in another clinical study using research products within the past 3 weeks.
Where it is running
1 location listed.
- Nanchang City, Jiangxi Province - Nanchang, Jiangxi, China